Serina Therapeutics, Inc. (SER)

Serina Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	3.16	3.15	0.59	3.46
Revenue Growth (YoY)	2436.14%	433.14%	-82.93%	-
Cost of Revenue	0.91	2.39	1.57	3.8
Gross Profit	2.25	0.77	-0.98	-0.33
Selling, General & Admin	8.39	3.89	1.29	1.3
Operating Expenses	13.51	3.89	1.29	1.3
Operating Income	-11.26	-3.13	-2.27	-1.63
Interest Expense	-0.77	-0.56	-0.02	-0
Interest & Investment Income	0.18	0.28	0	0.01
Other Non Operating Income (Expenses)	10.59	1.08	-0.12	0.21
EBT Excluding Unusual Items	-1.27	-2.33	-2.41	-1.42
Gain (Loss) on Sale of Investments	-	-	-0.01	-0.01
Gain (Loss) on Sale of Assets	-	-	-	-0.03
Other Unusual Items	-6.14	7.6	-0.27	0.19
Pretax Income	-7.4	5.27	-2.68	-1.26
Net Income	-7.35	5.27	-2.68	-1.26
Net Income to Common	-7.35	5.27	-2.68	-1.26
Shares Outstanding (Basic)	6	2	2	2
Shares Outstanding (Diluted)	6	4	2	2
Shares Change (YoY)	-5.45%	86.72%	0.01%	-
EPS (Basic)	-1.28	2.30	-1.25	-0.59
EPS (Diluted)	-1.28	1.46	-1.25	-0.59
Free Cash Flow	-12.51	-2.98	-2.09	-2.34
Free Cash Flow Per Share	-2.19	-0.74	-0.97	-1.09
Gross Margin	71.28%	24.30%	-165.95%	-9.64%
Operating Margin	-356.66%	-99.18%	-383.83%	-47.09%
Profit Margin	-232.86%	167.11%	-453.44%	-36.50%
Free Cash Flow Margin	-396.46%	-94.53%	-352.55%	-67.41%
EBITDA	-11.12	-3.04	-2.21	-1.6
EBITDA Margin	-	-96.37%	-	-46.13%
D&A For EBITDA	0.14	0.09	0.06	0.03
EBIT	-11.26	-3.13	-2.27	-1.63
EBIT Margin	-	-99.18%	-	-47.09%
Revenue as Reported	3.16	3.15	0.59	3.46

Source: S&P Capital IQ. Standard template. Financial Sources.